Karsinoma Pankreas

01Pathophysiology

Pancreatic ductal adenocarcinoma accounts for roughly 85% of all pancreatic malignancies and carries one of the worst prognoses of any solid tumor. The disease originates from the ductal epithelial cells of the exocrine pancreas. The KRAS oncogene is mutated in over 90% of cases, making it the earliest and most frequent genetic alteration. Progression follows a stepwise model through precursor lesions called pancreatic intraepithelial neoplasia (PanIN), where sequential loss of tumor suppressor genes occurs: CDKN2A (p16) is lost early, followed by TP53 and SMAD4 (DPC4) in later stages. Loss of SMAD4 correlates with widespread metastatic disease and is a poor prognostic marker.
The anatomical location of the tumor determines the clinical presentation. Approximately 60 to 70% of tumors arise in the head of the pancreas, where they compress or invade the common bile duct and the ampulla of Vater. This obstruction produces conjugated (direct) hyperbilirubinemia, leading to painless jaundice, dark urine (bilirubinuria), pale clay-colored stools (acholic stool), and pruritus. Because the obstruction is gradual and distal to the cystic duct, the gallbladder distends without inflammation, producing the Courvoisier sign: a palpable, nontender gallbladder in the setting of jaundice.
Tumors of the body and tail tend to remain clinically silent until they are advanced, because they do not obstruct the bile duct. These patients present later with vague epigastric pain radiating to the back (due to retroperitoneal invasion of the celiac plexus), profound weight loss, and cachexia.
New-onset diabetes mellitus in an older adult (typically over age 50, without obesity or family history) should raise suspicion for pancreatic cancer. The tumor produces diabetogenic mediators including amylin and adrenomedullin that impair beta-cell function and insulin signaling. This paraneoplastic diabetes may precede clinical diagnosis by 2 to 3 years.
Another classic paraneoplastic association is Trousseau syndrome, a migratory superficial thrombophlebitis caused by the tumor secreting mucins and tissue factor that activate the coagulation cascade. Unexplained recurrent venous thromboembolism in an older patient, particularly if resistant to anticoagulation, should prompt evaluation for an occult malignancy, with pancreatic cancer high on the differential.
Exocrine insufficiency develops when the tumor obstructs the main pancreatic duct, preventing pancreatic enzymes from reaching the duodenum. This results in malabsorption and steatorrhea (foul-smelling, greasy, floating stools), contributing further to weight loss and fat-soluble vitamin deficiency (vitamins A, D, E, K).

02Classification and Clinical Manifestation

03Diagnostic Workup

The best initial test when pancreatic cancer is suspected is a CT abdomen with intravenous contrast using a pancreatic protocol (dual-phase: arterial and portal venous phases). This modality identifies the primary tumor, evaluates involvement of critical vascular structures (the superior mesenteric artery, celiac axis, superior mesenteric vein, and portal vein), detects liver metastases, and determines surgical resectability. On imaging, ductal adenocarcinoma typically appears as a hypodense (low-attenuation) mass because of its dense desmoplastic stroma, which has poor blood supply relative to normal pancreatic parenchyma.
The most accurate test for obtaining a tissue diagnosis is EUS with fine-needle aspiration. EUS is superior to CT for detecting small tumors (less than 2 cm) and allows simultaneous tissue sampling. Tissue confirmation is essential before starting chemotherapy in patients with unresectable disease but is not always required before surgical resection if imaging is strongly suggestive and the tumor is resectable.
CA 19-9 is the most clinically useful serum tumor marker for pancreatic cancer. However, it is neither sensitive nor precise enough for screening. It is a sialylated Lewis blood group antigen, meaning that patients who are Lewis antigen-negative (approximately 5 to 10% of the population) will not produce CA 19-9 regardless of tumor burden. CA 19-9 can also be falsely elevated in any cause of biliary obstruction, cholangitis, or other gastrointestinal malignancies. Its primary utility is in monitoring treatment response and detecting recurrence after resection.
The double duct sign on CT or MRCP (simultaneous dilation of the common bile duct and the main pancreatic duct) is highly suggestive of a mass at the head of the pancreas and should be considered a red flag even if a discrete mass is not well-visualized.
If a patient presents with obstructive jaundice and is a surgical candidate, do not delay surgery for ERCP and biliary stenting unless the bilirubin is very high, the patient has cholangitis, or there will be a prolonged wait before surgery. Routine preoperative biliary drainage has not shown survival benefit and may increase infectious complications.

04Management and Treatment

Surgical resection is the only potentially curative treatment. For tumors in the head of the pancreas, the procedure of choice is the pancreaticoduodenectomy (Whipple procedure), which removes the head of the pancreas, the duodenum, the distal common bile duct, the gallbladder, and a portion of the stomach (classic Whipple) or preserves the pylorus (pylorus-preserving Whipple). Criteria for resectability include: no distant metastases, no involvement of the SMA or celiac axis, and a patent superior mesenteric vein/portal vein confluence.
For tumors in the body or tail, a distal pancreatectomy with splenectomy is performed. Unfortunately, body and tail tumors are rarely resectable at diagnosis because of their late presentation.
Following surgery, adjuvant chemotherapy is standard and has demonstrated improved overall survival. The current preferred regimen is modified FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) given every 2 weeks for 12 cycles (6 months total), based on the PRODIGE 24 trial. For patients who cannot tolerate this intensive regimen (older patients or those with borderline performance status), gemcitabine plus capecitabine for 6 months is an acceptable alternative based on the ESPAC-4 trial. Gemcitabine monotherapy (1,000 mg/m${}^2^2$ IV on days 1, 8, and 15 of a 28-day cycle for 6 cycles) remains an option for patients with poor functional status.
For borderline resectable tumors (those with limited vascular involvement that may preclude an R0 resection upfront), neoadjuvant chemotherapy with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel for 2 to 4 months is administered to attempt tumor downstaging before surgery.
In metastatic disease, treatment is palliative. FOLFIRINOX is used for patients with good performance status (ECOG 0 to 1) and offers superior survival compared to gemcitabine alone. Gemcitabine plus nab-paclitaxel (gemcitabine 1,000 mg/m${}^2^2$ plus nab-paclitaxel 125 mg/m${}^2^2$ IV on days 1, 8, and 15 of a 28-day cycle) is an alternative with a more favorable toxicity profile.
Palliative measures are critical in unresectable disease. Biliary obstruction is managed with an endoscopic self-expanding metal stent placed via ERCP. Gastric outlet obstruction may require endoscopic duodenal stenting or surgical gastrojejunostomy. Intractable pain from retroperitoneal invasion is treated with EUS-guided celiac plexus neurolysis using absolute alcohol injection. Exocrine insufficiency and malabsorption are managed with pancreatic enzyme replacement therapy (pancrelipase) taken with every meal and snack. Thromboembolism is treated with low-molecular-weight heparin, which is preferred over warfarin in malignancy-associated venous thromboembolism.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most tested concept in pancreatic cancer is the association of painless jaundice with a palpable, nontender gallbladder (Courvoisier sign), which points to malignant obstruction of the distal common bile duct and away from choledocholithiasis. A common trap is confusing this with gallstone disease: remember that in gallstone obstruction the gallbladder is chronically scarred and fibrotic, so it cannot distend, and the patient typically has colicky pain.
Another frequent pitfall involves new-onset diabetes mellitus in an older patient. Test-writers use this as a subtle clue buried in the stem. If the vignette describes a patient over 50 with recent-onset diabetes, weight loss, and vague abdominal complaints but no classic jaundice, students often anchor on the diabetes and miss the underlying malignancy, particularly because body and tail tumors do not cause jaundice.
Students also commonly confuse pancreatic ductal adenocarcinoma with autoimmune pancreatitis (IgG4-related disease). Both can present with obstructive jaundice and a pancreatic mass. The key discriminator is that autoimmune pancreatitis shows diffuse, "sausage-shaped" enlargement of the pancreas with a characteristic halo sign, elevated serum IgG4, and a dramatic response to steroids. Missing this diagnosis leads to unnecessary surgical resection.
On imaging questions, remember that ductal adenocarcinoma is hypodense (poorly enhancing) on contrast CT because of its dense desmoplastic stroma, whereas neuroendocrine tumors are hypervascular (avidly enhancing). This single imaging characteristic is one of the most reliable discriminators between the two and is repeatedly tested.
Finally, do not forget the Trousseau syndrome association. An exam question describing recurrent, migratory thrombophlebitis or unprovoked DVT/PE in an older patient with weight loss should trigger consideration of an occult pancreatic malignancy. The core competency being tested here is your ability to connect paraneoplastic and systemic manifestations to an underlying cancer rather than treating the thrombosis in isolation.